The comparison of this data shows some common characteristics observed in all Regions: the presence of working group and criteria for the eligibility of patients and identification of prescribing centers. Since 2013 all Regions have identified a working group (except Liguria) and detailed the patient profile to prioritization (except Liguria and Sicily). Regarding identification of prescription center, as showed in Figure 1 and Table 3 , the majority of Regions adapted the criteria based on the presence of specialized diagnostic labs and multidisciplinary team. N/A N/A P P P P P P P P P P P P P P Besides these characteristics, there is a substantial heterogeneity in Regional guidelines, especially regarding budget allocation, management model and follow up system. Indeed, if in some Regions like Basilicata and Veneto there is a specific budget allocation (respectively €1,2 ml and €12 ml in 2014), the management model is based on Hub and Spoke system and the follow up mechanism is clearly set up, in other Regions like Lombardy and Liguria the guidelines are more vague, detailing only few criteria. The budget allocated, where available, is showed in 
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Patients priority P P P P P P P P P P P P These Regional differences are confirmed by other two data: the timespan between the market authorization (AIC) of the Triple Therapy (TT) for HCV patients and the integration in Regional guidelines (GL) and the number of prescribing centers per million inhabitants. The wide variety of results is presented in table 6 and table 7 , with a range between 17 and 147 days (respectively in Veneto and in Emilia Romagna) for time to TT inclusion in Guidelines and with a range between 1,85 and 6,92 of prescribing centers per million inhabitants (respectively in Veneto and in Basilicata).
CONClUsiONs
The study demonstrate that, with a view to the future novel drugs, a common disease management model, including common guidelines and organizational model, is essential to avoid regional disparities in HCV therapies access. 
